Long-Term Association of Venous Thromboembolism With Frailty, Physical Functioning, and Quality of Life: The Atherosclerosis Risk in Communities Study
- PMID: 32476561
- PMCID: PMC7429054
- DOI: 10.1161/JAHA.119.015656
Long-Term Association of Venous Thromboembolism With Frailty, Physical Functioning, and Quality of Life: The Atherosclerosis Risk in Communities Study
Abstract
Background Relatively little is known about the long-term consequences of venous thromboembolism (VTE) on physical functioning. We compared long-term frailty status, physical function, and quality of life among survivors of VTE with survivors of coronary heart disease (CHD) and stroke, and with those without these diseases. Methods and Results Cases of VTE, CHD, and stroke were continuously identified since ARIC (Atherosclerosis Risk in Communities Study) recruitment during 1987 to 1989. Functional measures were objectively captured at ARIC clinic visits 5 (2011-2013) and 6 (2016-2017); quality of life was self-reported. The 6161 participants at visit 5 were, on average, 75.7 (range, 66-90) years of age. By visit 5, 3.2% had had a VTE, 6.9% CHD, and 3.4% stroke. Compared with those without any of these conditions, VTE survivors were more likely to be frail (odds ratio [OR], 3.11; 95% CI, 1.80-5.36) and have low (<10) versus good scores on the Short Physical Performance Battery (OR, 3.59; 95% CI, 2.36-5.47). They also had slower gait speed, less endurance, and lower physical quality of life. VTE survivors were similar to coronary heart disease and stroke survivors on categorical frailty and outcomes on Short Physical Performance Battery assessment. When score on the Short Physical Performance Battery instrument was modeled continuously, VTE survivors performed better than stroke survivors but worse than CHD survivors. Conclusions VTE survivors had triple the odds of frailty and poorer physical function than those without the vascular diseases considered. Their function was somewhat worse than that of CHD survivors, but better than stroke survivors. These findings suggest that VTE patients may benefit from additional efforts to improve postevent physical functioning.
Keywords: frailty; physical function; quality of life; venous thromboembolism.
Figures


Similar articles
-
Frailty and risk of venous thromboembolism in older adults: the Atherosclerosis Risk in Communities Study.J Thromb Haemost. 2025 May;23(5):1531-1538. doi: 10.1016/j.jtha.2025.01.006. Epub 2025 Jan 31. J Thromb Haemost. 2025. PMID: 39894445
-
American Heart Association's Life's Simple 7 and risk of venous thromboembolism: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.J Am Heart Assoc. 2015 Feb 27;4(3):e001494. doi: 10.1161/JAHA.114.001494. J Am Heart Assoc. 2015. PMID: 25725088 Free PMC article.
-
Long-term association between frailty and health-related quality of life among survivors of critical illness: a prospective multicenter cohort study.Crit Care Med. 2015 May;43(5):973-82. doi: 10.1097/CCM.0000000000000860. Crit Care Med. 2015. PMID: 25668751
-
Multimorbidity, comorbidity, frailty, and venous thromboembolism.Haematologica. 2024 Dec 1;109(12):3852-3859. doi: 10.3324/haematol.2023.284579. Haematologica. 2024. PMID: 39618295 Free PMC article. Review.
-
Frailty and functional outcomes after open and endovascular procedures for patients with peripheral arterial disease: A systematic review.J Vasc Surg. 2020 Jan;71(1):297-306.e1. doi: 10.1016/j.jvs.2018.12.060. Epub 2019 Jul 19. J Vasc Surg. 2020. PMID: 31331651
Cited by
-
Development and internal and external validation of a nomogram model for frailty risk among hospitalised older people using comprehensive geriatric assessment data.BMC Geriatr. 2023 Nov 2;23(1):712. doi: 10.1186/s12877-023-04426-8. BMC Geriatr. 2023. PMID: 37919663 Free PMC article.
-
Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation.J Clin Med. 2022 Oct 10;11(19):5970. doi: 10.3390/jcm11195970. J Clin Med. 2022. PMID: 36233833 Free PMC article. Review.
-
The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization.Res Pract Thromb Haemost. 2024 Sep 16;8(7):102573. doi: 10.1016/j.rpth.2024.102573. eCollection 2024 Oct. Res Pract Thromb Haemost. 2024. PMID: 40206268 Free PMC article.
-
Epidemiology and prevention of venous thromboembolism.Nat Rev Cardiol. 2023 Apr;20(4):248-262. doi: 10.1038/s41569-022-00787-6. Epub 2022 Oct 18. Nat Rev Cardiol. 2023. PMID: 36258120 Free PMC article. Review.
-
Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease-a systematic review and meta-analysis.J Nephrol. 2025 Jan;38(1):111-126. doi: 10.1007/s40620-024-02130-3. Epub 2024 Nov 29. J Nephrol. 2025. PMID: 39614034 Free PMC article.
References
-
- Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation. 2019;e56–e528. - PubMed
-
- Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real‐world population: the Q‐VTE Study Cohort. Am J Med. 2013;832.e13–832.e21. - PubMed
-
- Gaertner S, Cordeanu EM, Nouri S, Faller AM, Frantz AS, Mirea C, Bilbault P, Ohlmann P, Le Ray I, Stephan D. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6‐month outcomes. Int J Cardiol. 2017;103–109. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical